TIF and the Angel Mama Foundation visit Reforgene to advance global access for thalassemia gene medicine

On March 19, 2026, a delegation of the Thalassaemia International Federation (TIF) and the Beijing Angel Mama Charity Foundation visited Guangzhou Reforgene Medicine Co., Ltd. for in-depth exchanges and discussions on topics including innovative R&D of thalassemia gene editing treatment, global strategic cooperation, patient rights protection and technology accessibility. The visit brought together internationally authoritative experts and domestic public welfare forces, and was not only high recognition of Reforgene's leading strength in thalassemia gene editing treatment, but also built an important cooperation bridge for the coordinated development of global thalassemia prevention and treatment.

The visiting delegation was authoritative and professional, composed of authoritative scholars and clinical experts in thalassemia from Italy, Cyprus, Greece and Indonesia on the TIF Medical Advisory Committee, including Piga Antonio Giulio, Dimitrios Farmakis, Evangelia Yannaki and Ludi Dhyani Rahmartani, as well as Qiu Lili, Director of the Beijing Angel Mama Charity Foundation, Mao Yutao, Deputy Secretary-General, and Xia Yu, Head of the Cooperation Development Department. Dr. Liang Junbin, CEO of Reforgene, led the team to receive the delegation and host the discussion.

During the discussion, Reforgene gave a detailed introduction to the company's innovative strategic layout for gene editing medicines, the clinical research progress of its thalassemia product RM001, and other key technological achievements. Combining global thalassemia prevention and treatment practices and the frontier of gene therapy, TIF experts conducted in-depth discussions with the Reforgene team on core topics such as technical routes, clinical efficacy, international standards and full-cycle patient protection. The two sides reached a high degree of consensus on directions including technology sharing, experience exchange and global promotion.

After the discussion, the delegation visited Reforgene's R&D laboratories and GMP-standard production workshops to systematically understand the R&D progress of the thalassemia gene editing medicine pipeline and the full-chain quality control system. Reforgene's rigorous R&D processes and world-class production quality control standards received unanimous praise and high recognition from the delegation.

As the only innovative enterprise in the world to have achieved cures for both alpha- and beta-thalassemia, Reforgene has established a significant leading advantage in the thalassemia gene medicine field. Taking this exchange as an opportunity, the company will further absorb advanced international experience, accelerate technological innovation and the application of drug achievements, deepen global multi-party cooperation, promote thalassemia gene medicines with excellent clinical efficacy to the world, and provide more patients with cure and new life.